- Home
- ACRS vs BSET Comparison
ACRS vs BSET Comparison
Compare ACRS & BSET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- BSET
- Stock Information
- Founded
- ACRS 2012
- BSET 1902
- Country
- ACRS United States
- BSET United States
- Employees
- ACRS N/A
- BSET N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- BSET Home Furnishings
- Sector
- ACRS Health Care
- BSET Consumer Discretionary
- Exchange
- ACRS Nasdaq
- BSET Nasdaq
- Market Cap
- ACRS 165.7M
- BSET 135.3M
- IPO Year
- ACRS 2015
- BSET 1987
- Fundamental
- Price
- ACRS $1.95
- BSET $16.22
- Analyst Decision
- ACRS Strong Buy
- BSET
- Analyst Count
- ACRS 9
- BSET 0
- Target Price
- ACRS $9.25
- BSET N/A
- AVG Volume (30 Days)
- ACRS 822.9K
- BSET 21.4K
- Earning Date
- ACRS 11-05-2025
- BSET 10-08-2025
- Dividend Yield
- ACRS N/A
- BSET 4.98%
- EPS Growth
- ACRS N/A
- BSET N/A
- EPS
- ACRS N/A
- BSET 0.28
- Revenue
- ACRS $16,789,000.00
- BSET $326,469,000.00
- Revenue This Year
- ACRS N/A
- BSET $3.18
- Revenue Next Year
- ACRS $7.02
- BSET $3.57
- P/E Ratio
- ACRS N/A
- BSET $57.20
- Revenue Growth
- ACRS N/A
- BSET N/A
- 52 Week Low
- ACRS $1.05
- BSET $13.58
- 52 Week High
- ACRS $5.17
- BSET $19.75
- Technical
- Relative Strength Index (RSI)
- ACRS 56.00
- BSET 46.14
- Support Level
- ACRS $1.81
- BSET $16.36
- Resistance Level
- ACRS $2.16
- BSET $17.12
- Average True Range (ATR)
- ACRS 0.12
- BSET 0.49
- MACD
- ACRS -0.03
- BSET -0.05
- Stochastic Oscillator
- ACRS 41.43
- BSET 20.61
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About BSET Bassett Furniture Industries Incorporated
Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.